Records 1 - 30
| DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
British journal of clinical pharmacology 2021 Nov .
Božina Nada, Bili? Ivan, Ganoci Lana, Šimi?evi? Livija, Pleština Stjepko, Lešnjakovi? Lucija, Trkulja Vladim
| UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
The oncologist 2021 Mar .
Bandyopadhyay Ankan, Sharma Siddharth, Behera Digambar, Singh Navne
| Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen.
Pharmacogenomics and personalized medicine 2021 14 369-377.
Zhu Xiaoqin, Zhu Jia, Sun Feifei, Zhen Zijun, Zhou Dalei, Lu Suying, Huang Junting, Que Yi, Zhang Lian, Cai Ruiqing, Wang Juan, Zhang Yizh
| Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis.
Bioscience reports 2020 Sep .
Zhu Xiaoyun, Ma Ruchao, Ma Xin, Yang Ga
| Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
BMC gastroenterology 2020 Apr 20 (1): 96.
Chen Shaojun, Hua Li, Feng Chengjun, Mo Qia, Wei Mengzhuan, Shen Yongqi, Lin Zhan, Li Guisheng, Xu Junyi, Guo Chengxian, Huang Haix
| Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.
Cancer science 2019 Feb 110 (2): 707-716.
Shirasu Hiromichi, Todaka Akiko, Omae Katsuhiro, Fujii Hirofumi, Mizuno Nobumasa, Ozaka Masato, Ueno Hideki, Kobayashi Satoshi, Uesugi Kazuhiro, Kobayashi Noritoshi, Hayashi Hideyuki, Sudo Kentaro, Okano Naohiro, Horita Yosuke, Kamei Keiko, Yukisawa Seigo, Kobayashi Marina, Fukutomi Aki
| A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
Cancer 2019 Jan .
Sharma Manish R, Joshi Smita S, Karrison Theodore G, Allen Kenisha, Suh Grace, Marsh Robert, Kozloff Mark F, Polite Blase N, Catenacci Daniel V T, Kindler Hedy
| Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.
Cancer chemotherapy and pharmacology 2019 Jan 83 (1): 123-129.
Fujii Hironori, Yamada Yunami, Watanabe Daichi, Matsuhashi Nobuhisa, Takahashi Takao, Yoshida Kazuhiro, Suzuki Ak
| UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan.
Cancer science 2018 Sep .
Kimura Kei, Yamano Tomoki, Igeta Masataka, Imada Ayako, Jihyung Song, Babaya Akihito, Hamanaka Michiko, Kobayashi Masayoshi, Tsukamoto Kiyoshi, Noda Masafumi, Ikeda Masataka, Tomita Naohi
| [Relationship between UGT1A1 gene polymorphisms and irinotecan-induced severe adverse events].
Zhonghua zhong liu za zhi [Chinese journal of oncology] 2018 Aug 40 (8): 594-599.
Wang X F, Ma C, Gong F F, Yi S Y, Xing G C, Wang K J, Yang Q, Cao
| UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.
Asia-Pacific journal of clinical oncology 2018 Jun .
Yang Yuwei, Zhou MengMeng, Hu Mingjun, Cui Yanjie, Zhong Qi, Liang Ling, Huang F
| A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study).
Cancer medicine 2017 Nov .
Ishiguro Hiroshi, Saji Shigehira, Nomura Shogo, Tanaka Sunao, Ueno Takayuki, Onoue Masahide, Iwata Hiroji, Yamanaka Takeharu, Sasaki Yasutsuna, Toi Masaka
| Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer.
Oncology letters 2017 Nov 14 (5): 5743-5752.
Wang Yang, Yi Cuihua, Wang Yawei, Li Hui, Li Bei, Wang Dan, Du Jintong, Liu Lian, Wang Xiuw
| A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).
International journal of clinical oncology 2017 Oct 22 (5): 913-920.
Ando Koji, Emi Yasunori, Suenaga Toyokuni, Hamanoue Masahiro, Maekawa Soichiro, Sakamoto Yasuo, Kai Seiichiro, Satake Hironaga, Shimose Takayuki, Shimokawa Mototsugu, Saeki Hiroshi, Oki Eiji, Sakai Kenji, Akagi Yoshito, Baba Hideo, Maehara Yoshihiko,
| UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Clinical laboratory 2017 Sep 63 (9): 1339-1346.
Peng Hongwei, Duan Zhouping, Pan Decheng, Wen Jinhua, Wei Xiaoh
| Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
BMC cancer 2017 Jun 17 (1): 437.
Liu Dan, Li Jian, Gao Jing, Li Yanyan, Yang Rui, Shen L
| UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
Cancer chemotherapy and pharmacology 2017 Jun 79 (6): 1109-1117.
Chen Xuewei, Liu Liping, Guo Zhihua, Liang Wenhua, He Jiaxi, Huang Liyan, Deng Qiuhua, Tang Hailing, Pan Hui, Guo Minzhang, Liu Yang, He Qihua, He Jianxi
| Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.
Cancer biology & therapy 2017 Feb 1-8.
Cai Xun, Tian Chuan, Wang Liwei, Zhuang Rongyuan, Zhang Xiaowei, Guo Yuanbiao, Lu Hongmin, Wang Hui, Li Xiaoyu, Gao Junwei, Li Qi, Wang Chunga
| Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
Thoracic cancer 2017 Jan 8 (1): 40-45.
Fukuda Minoru, Shimada Midori, Kitazaki Takeshi, Nagashima Seiji, Hashiguchi Kohji, Ebi Noriyuki, Takayama Koichi, Nakanishi Yoichi, Semba Hiroshi, Harada Taishi, Seto Takashi, Okamoto Isamu, Ichinose Yukito, Sugio Ken
| Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan 2017 02 37 (1): 35-42.
Deng Bo, Jia Liqun, Tan Huangying, Lou Yanni, Li Xue, Li Yuan, Yu Li
| Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.
Journal of Cancer 2017 8 (4): 691-703.
Liu Xing-Han, Lu Jun, Duan Wei, Dai Zhi-Ming, Wang Meng, Lin Shuai, Yang Peng-Tao, Tian Tian, Liu Kang, Zhu Yu-Yao, Zheng Yi, Sheng Qian-Wen, Dai Zhi-J
| Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy.
OncoTargets and therapy 2017 10 3071-3081.
Bai Yu, Wu Hai-Wei, Ma Xu, Liu Ying, Zhang Yan-H
| UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens.
Oncology letters 2016 Nov 12 (5): 4231-4237.
Cui Chengxu, Shu Chang, Cao Dandan, Yang Yi, Liu Junbao, Shi Shuping, Shao Zhujun, Wang Nan, Yang Ting, Liang Hao, Zou Shanshan, Hu Songni
| Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Aug .
Toffoli Giuseppe, Sharma Manish R, Marangon Elena, Posocco Bianca, Gray Elizabeth, Mai Quan, Buonadonna Angela, Polite Blase N, Miolo Gianmaria, Tabaro Gianna, Innocenti Federi
| A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.
Journal of cancer research and clinical oncology 2016 May .
Li Jing, Yu Qianqian, Fu Shengling, Xu Min, Zhang Tao, Xie Conghua, Feng Jueping, Chen Jigui, Zang Aihua, Cai Yixin, Fu Qiang, Liu Shan, Zhang Mingsheng, Hong Qiu, Huang Liu, Yuan Xiangl
| UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer.
Cancer chemotherapy and pharmacology 2016 May .
Xu Chunlei, Tang Xushan, Qu Yanli, Keyoumu Saifuding, Zhou Ning, Tang Yo
| A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle.
Cancer chemotherapy and pharmacology 2016 Apr .
Burris Howard A, Infante Jeffrey R, Anthony Greco F, Thompson Dana S, Barton John H, Bendell Johanna C, Nambu Yoshihiro, Watanabe Noriko, Jones Suzanne
| Effects of UGT1A1*6, UGT1A1*28, and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients.
International journal of clinical pharmacology and therapeutics 2016 Feb .
Yan Liang, Wang Xiao-Fei, Wei Lu-Man, Nie Ya-Li, Liu Jing-Yang, Zhang Li-Ro
| Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
Pharmacogenomics 2016 09 17 (14): 1483-90.
Bins Sander, Lenting Anne, El Bouazzaoui Samira, van Doorn Leni, Oomen-de Hoop Esther, Eskens Ferry Alm, van Schaik Ron Hn, Mathijssen Ron
| Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Trials 2016 17 (1): 46.
Yeh Yung-Sung, Tsai Hsiang-Lin, Huang Ching-Wen, Wang Jui-Ho, Lin Yi-Wen, Tang Hsiu-Chih, Sung Yung-Chuan, Wu Chang-Chieh, Lu Chien-Yu, Wang Jaw-Yu